文献速递垂体与肾上腺疾病

原发性醛固酮增多症综合征的演变:更新诊疗路径

Evolution of the Primary Aldosteronism Syndrome: Updating the Approach.
PubMed 文献 · J Clin Endocrinol Metab · 2020-01-01

本文综述证据表明原发性醛固酮增多症是常见的未被充分识别的综合征,表现为不依赖肾素的醛固酮生成。该生化表型在血压正常和高血压人群中均可检测到,其程度与血压升高、高血压及心血管疾病风险、以及盐皮质激素受体拮抗剂治疗后的血压下降相关。扩大筛查指征并采用基于病理生理的方法(强调肾素抑制背景下不适当的醛固酮生成)可提高诊断和治疗收益。

要点

  • 原发性醛固酮增多症是不依赖肾素的醛固酮生成,常见但多未被识别。
  • 该生化表型程度与血压升高、高血压及心血管疾病风险平行。
  • 扩大筛查指征并简化诊断路径可提高诊断和治疗收益。

核心结论

  • 原发性醛固酮增多症是常见的肾素非依赖性醛固酮生成综合征,参与高血压和心血管疾病发病。
  • 扩大筛查指征并简化诊断方法有助于实施针对性治疗。

研究设计与样本

  • 综述,证据来自已发表的指南和PubMed检索研究,检索词包括primary aldosteronism、aldosterone、renin和hypertension,并补充作者个人知识、研究经验和临床实践。

主要发现

  • 肾素非依赖性醛固酮生成是常见表型,严重时诊断为原发性醛固酮增多症,较轻时多未被识别。
  • 该生化表型可在血压正常和高血压个体中检测到。
  • 该表型程度与血压升高程度、新发高血压和心血管疾病风险、以及盐皮质激素受体拮抗剂治疗后的血压下降可能性和幅度平行。

临床怎么用

  • 扩大原发性醛固酮增多症的筛查指征。
  • 采用基于病理生理的方法,强调肾素抑制背景下不适当的醛固酮生成。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

CONTEXT: New approaches are needed to address the evolution of the primary aldosteronism syndrome and to increase its recognition. Herein, we review evidence indicating that primary aldosteronism is a prevalent syndrome that is mostly unrecognized, and present a pragmatic and pathophysiology-based approach to improve diagnosis and treatment. METHODS: Evidence was gathered from published guidelines and studies identified from PubMed by searching for primary aldosteronism, aldosterone, renin, and hypertension. This evidence was supplemented by the authors' personal knowledge, research experience, and clinical encounters in primary aldosteronism. INTERPRETATION OF EVIDENCE: Renin-independent aldosterone production is a prevalent phenotype that is diagnosed as primary aldosteronism when severe in magnitude, but is largely unrecognized when milder in severity. Renin-independent aldosterone production can be detected in normotensive and hypertensive individuals, and the magnitude of this biochemical phenotype parallels the magnitude of blood pressure elevation, the risk for incident hypertension and cardiovascular disease, and the likelihood and magnitude of blood pressure reduction with mineralocorticoid receptor antagonist therapy. Expansion of the indications to screen for primary aldosteronism, combined with the use of a pathophysiology-based approach that emphasizes inappropriate aldosterone production in the context of renin suppression, will substantially increase the diagnostic and therapeutic yields for primary aldosteronism. CONCLUSIONS: The landscape of primary aldosteronism has evolved to recognize that it is a prevalent syndrome of renin-independent aldosterone production that contributes to the pathogenesis of hypertension and cardiovascular disease. Expanding screening indications and simplifying the diagnostic approach will enable implementation of targeted treatment for primary aldosteronism.

来源:J Clin Endocrinol Metab,查看原文。版权归原作者所有。

引用

  1. Vaidya A, Carey RM. Evolution of the Primary Aldosteronism Syndrome: Updating the Approach. J Clin Endocrinol Metab. 2020. PMID: 32865201. doi:10.1210/clinem/dgaa606

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。